scholarly journals Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor   blockers in ankylosing spondylitis

2004 ◽  
Vol 63 (6) ◽  
pp. 665-670 ◽  
Author(s):  
M Rudwaleit
Keyword(s):  
Ankylosing Spondylitis ◽  
Clinical Response ◽  
Tumour Necrosis Factor ◽  
Tumour Necrosis ◽  
Necrosis Factor

MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis

2007 ◽  
Vol 67 (9) ◽  
pp. 1276-1281 ◽  
Author(s):  
M Rudwaleit ◽  
S Schwarzlose ◽  
E S Hilgert ◽  
J Listing ◽  
J Braun ◽  
...  
Keyword(s):  
Ankylosing Spondylitis ◽  
Clinical Response ◽  
Tumour Necrosis Factor ◽  
Tumour Necrosis ◽  
Necrosis Factor

Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry

2010 ◽  
Vol 69 (11) ◽  
pp. 2002-2008 ◽  
Author(s):  
Bente Glintborg ◽  
Mikkel Østergaard ◽  
Niels Steen Krogh ◽  
Lene Dreyer ◽  
Hanne Lene Kristensen ◽  
...  
Keyword(s):  
Regression Analysis ◽  
Ankylosing Spondylitis ◽  
Disease Activity ◽  
Clinical Response ◽  
Tumour Necrosis Factor ◽  
Tumour Necrosis ◽  
Cox Regression Analysis ◽  
Drug Survival ◽  
Tnfα Inhibitor ◽  
Necrosis Factor

ObjectivesTo use prospectively registered data from the Danish nationwide rheumatological database (DANBIO) to describe disease activity, clinical response, treatment duration and predictors of drug survival (ie, number of days individual patients maintained treatment) and clinical response among patients with ankylosing spondylitis (AS) receiving their first treatment series with a tumour necrosis factor α (TNFα) inhibitor.Methods842 TNFα inhibitor naive patients with AS were identified in DANBIO. Clinical response, drug survival and predictors thereof were investigated. ‘Clinical response’ was defined as a 50% or 20 mm reduction in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) within 6 months compared with baseline. Achievement of a BASDAI <40 mm within 6 months was used as a second response parameter.Results603 patients (72%) were men, disease duration 5 (1–13) years (median (IQR), age 41 (32–50) years. 445 (53%) received infliximab, 247 (29%) adalimumab and 150 (18%) etanercept. Parameters at baseline/1-year follow-up were: C-reactive protein (CRP): 14 (7–27)/5 (2–10) mg/l, BASDAI 59 (44–72)/21 (8–39) mm, Bath Ankylosing Spondylitis Functional Index (BASFI) 50 (34–67)/24 (9–45) mm, Bath Ankylosing Spondylitis Metrology Index 40 (20–50)/20 (10–40) mm. Within 6 months, 407/644 patients (63%) achieved a clinical response. Median drug survival was 4.3 years. One- and 2-year survival rates were 74% and 63%, respectively. Baseline characteristics associated with longer drug survival were male gender, CRP >14 mg/l and low visual analogue scale fatigue (Cox regression analysis). Age, TNFα inhibitor and methotrexate use were insignificant. CRP >14 mg/l, lower BASFI and younger age at baseline was associated with clinical response and achievement of a BASDAI <40 mm (logistic regression analysis).ConclusionTNFα inhibitors provide a rapid and sustained decrease of disease activity among patients with AS in clinical practice. Factors associated with continued treatment, clinical response and achievement of a BASDAI <40 mm were identified.

Sign in / Sign up

Export Citation Format

Share Document